Emcure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 250.00 Cr
- Paid Up Capital ₹ 189.43 Cr
- Company Age 43 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1,673.55 Cr
- Satisfied Charges ₹ 6,733.21 Cr
- Revenue Growth -8.17%
- Profit Growth -64.18%
- Ebitda -44.82%
- Net Worth 7.55%
- Total Assets 6.77%
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited (EPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 16 April 1981 and has a history of 43 years and nine months. Its registered office is in Pune, Maharashtra, India.
The Corporate was formerly known as Emcure Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 250.00 Cr and a paid-up capital of Rs 189.43 Cr.
The company currently has active open charges totaling ₹1,673.55 Cr. The company has closed loans amounting to ₹6,733.21 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Emcure Pharmaceuticals Limited India are Satish Mehta as Ceo, Tajuddin Shaikh as Cfo, and Chetan Sharma as Company Secretary. Mukund Gurjar, Sunil Mehta, Satish Mehta, and Seven other members serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24231PN1981PLC024251
- Company No.
024251
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Apr 1981
- Date of AGM
05 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Pune
Industry
What products or services does Emcure Pharmaceuticals Limited offer?
Emcure Pharmaceuticals Limited offers a wide range of products and services, including Common Disease Medicines, Allopathic Cough Syrup, Anti Inflammatory Drugs, Pharma Ingredients & Raw Materials, Antipyretic and Analgesic API, Pharmaceutical Medicine, Torex Cough Syrup, Infusion Syringes & Supplies, Syringes, Cosmetics, Hair & Beauty Products.
Who are the key members and board of directors at Emcure Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Mehta  | Managing Director | 16-Apr-1981 | Current |
| Tajuddin Shaikh | CFO | 16-Apr-2021 | Current |
| Chetan Sharma | Company Secretary | 26-Jun-2023 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vidya Yeravdekar | Director | 16-Apr-2021 | Current |
Shailesh Ayyangar  | Director | 16-Apr-2021 | Current |
| Namita Thapar | Whole-Time Director | 28-Jul-2014 | Current |
| Mukund Gurjar | Whole-Time Director | 23-Jul-2001 | Current |
| Berjis Desai | Director | 03-Apr-1997 | Current |
| Sunil Mehta | Whole-Time Director | 05-Jun-2013 | Current |
Financial Performance of Emcure Pharmaceuticals.
Emcure Pharmaceuticals Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.17% decrease. The company also saw a substantial fall in profitability, with a 64.18% decrease in profit. The company's net worth moved up by a moderate rise of 7.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emcure Pharmaceuticals?
In 2023, Emcure Pharmaceuticals had a promoter holding of 48.05% and a public holding of 51.94%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Noveltech Feeds Private LimitedShailesh Ayyangar is a mutual person
Man Infraconstruction LimitedBerjis Desai is a mutual person
Inventurus Knowledge Solutions LimitedBerjis Desai is a mutual person
Hikal LimitedBerjis Desai is a mutual person
Future Generali India Life Insurance Company LimitedPalamadai Jayakumar is a mutual person
Ambit Private LimitedBerjis Desai is a mutual person
Charges (Loans)
₹1,673.55 Cr
₹6,733.21 Cr
Charges Breakdown by Lending Institutions
- Others : 1090.00 Cr
- Axis Bank Limited : 411.48 Cr
- Tata Capital Financial Services Limited : 170.00 Cr
- Hdfc Bank Limited : 2.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 May 2024 | Others | ₹100.00 Cr | Open |
| 20 Dec 2023 | Tata Capital Financial Services Limited | ₹50.00 Cr | Open |
| 04 May 2023 | Others | ₹175.00 Cr | Open |
| 27 Jun 2022 | Others | ₹100.00 Cr | Open |
| 25 Mar 2022 | Others | ₹275.00 Cr | Open |
How Many Employees Work at Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a workforce of 6414 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emcure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emcure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
